A large study reveals no association between APOE and Parkinson's disease

NEUROBIOLOGY OF DISEASE

卷:46

Article

Federoff, Monica¹  Jimenez-Rolando, Belen¹  Nalls, Michael A.¹  Singleton, Andrew B.¹ 

[1] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA

关键词: Parkinson's disease;    Genetics;    APOE;   

DOI  :  10.1016/j.nbd.2012.02.002

来源: Elsevier

【 摘 要 】

Background: Research focusing on the role of APOE in Parkinson's disease (PD) has been largely inconclusive. creating a broad discrepancy in association studies. Objective: To elucidate the role of APOE alleles in PD risk by studying a large sample size and controlling for population substructure. Patients and methods: In total, 3465 case and control samples were genotyped, obtained from the NINDS Neurogenetics repository. Results: No significant differences in epsilon 4 dosages exist between PD cases and controls. The frequency of epsilon 4 carriers differed slightly between cases and controls at 24% (580/2412) and 26% (270/1053), respectively. Likewise, mean dosages of APOE 62 were not significantly different between cases and controls. APOE epsilon 2 carriers were observed at a frequency of 13.6% (329/2412) among cases and 15% (158/1053) among controls. Logistic regression models evaluating PD as possibly associated with epsilon 4 or epsilon 2 carrier status and allele dosages yielded no significant results. The mean MMSE score among all PD cases was 28.35 (SD = 2.58) and memory loss was reported in only 11.9% (105/879) of cases. Linear regression models comparing MMSE scores as predicted by epsilon 4 or epsilon 2 carrier status and allele dosages were not significant. Conclusions: There is no association between APOE epsilon alleles and Parkinson's disease. Published by Elsevier Inc.

【 授权许可】

Free